Eloxx Pharmaceuticals, Inc.
ELOXD
OTC PK
| 03/31/2026 | 03/31/2025 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -3.75M | -1.71M | -4.34M | -6.23M | -6.32M |
| Total Depreciation and Amortization | -- | -- | 185.00K | 186.00K | 178.00K |
| Total Amortization of Deferred Charges | 7.00K | 236.00K | 47.00K | 120.00K | 144.00K |
| Total Other Non-Cash Items | -10.00K | 45.00K | 614.00K | 1.02M | 606.00K |
| Change in Net Operating Assets | -1.70M | 2.63M | 1.43M | -1.91M | -270.00K |
| Cash from Operations | -5.45M | 1.20M | -2.07M | -6.81M | -5.66M |
| Capital Expenditure | -- | -- | -- | -- | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | 14.00K | 11.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 14.00K | 11.00K | 0.00 |
| Total Debt Issued | -- | 390.00K | -- | -- | -- |
| Total Debt Repaid | -- | -1.26M | 0.00 | -7.50M | -- |
| Issuance of Common Stock | 7.03M | -- | 1.43M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 312.00K |
| Cash from Financing | 7.03M | -865.00K | 1.43M | -7.50M | 312.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.58M | 339.00K | -624.00K | -14.30M | -5.35M |